Latest Headlines

Latest Headlines

Vaxxas scores $20M to develop needle-free vaccines

Vaxxas announced Monday that it raised $20 million in a Series B round, which will be used to advance a series of clinical programs and to develop a pipeline of new vaccine products using the company's needle-free Nanopatch platform.

Vaxxas banks $20M for its needle-free injection platform

Biotech upstart Vaxxas raised $20 million in the first close of its B round, cash that'll help the biotech develop a needle-free technology for vaccinations.

Vaxxas' nanopatch garners WHO support in search of polio vax application

Australian nanopatch developer Vaxxas signed on with the World Health Organization this week in an effort to co-opt the company's patch for use with the polio vaccine. The WHO will help fund the research and move it through preclinical and clinical studies as the organization seeks to make polio a thing of the past.

Merck taps Vaxxas for Nanopatch vaccine delivery

Drug giant Merck ($MRK) will team up with Australia's Vaxxas to research the startup's drug-delivery patch that targets vaccine to immunological cells just below the skin's surface.

Merck taps startup from Down Under for vaccine patch

The deal provides Vaxxas with a major pharma collaborator as it relocates business operations from Australia to Cambridge, MA, where new CEO David Hoey hopes to find additional partners, he told FierceBiotech in an interview.

Start-up Vaxxas lands $16.46M for vaccine nanopatch

Australia's Vaxxas has garnered about $16.46 million in venture capital financing to support development of its Nanopatch delivery technology, which the company says could drastically change how